Business
Arcellx is a clinical-stage biotechnology company developing D-Domain powered immunotherapies, led by anitocabtagene autoleucel, or anito-cel, for multiple myeloma.
Arcellx revenue fell and burn deepened as anito-cel moved toward a 2026 FDA decision.
The read at a glance✓ Audited against SEC data
- Business mix — D-Domain CAR-T immunotherapy platformNote
- Revenue — Revenue -79.4% to $22.3MWatch
- Profitability — Net loss widened to $228.9MWatch
- Cash burn — Free cash flow was -$212.6MWatch
- Balance sheet — Equity -11.5% to $402.4MWatch
- Insiders — 0 buys / 17 sellsWatch
- Accounting — Altman-Z distressWatch
Leadership changes
From Arcellx, Inc.'s own filings, the day they're filed.
- Andrew Galligan · Directors · departureeff. 2025-03-18
- Kristin Myers · Directors · departureeff. 2025-03-18
- Derek Yoon · Directors · departure
Latest filings
- 8-K · Company announcement2026-04-28
- 10-K · Annual report2026-02-26
- 8-K · Company announcement2026-02-23
- 8-K · Company announcement2025-12-08
- 8-K · Company announcement2025-11-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Arcellx, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.